Biosafety startup Red Queen Bio uses AI technology to pre-design antibody drugs to combat unknown novel pathogens that may be designed or modified by AI systems in the future. The company, led by OpenAI, said it has raised $36 million so far. The company plans to begin human clinical trials of its avian influenza and other influenza virus family antibody drugs next year.

Biosafety startup Red Queen Bio uses AI technology to pre-design antibody drugs to combat unknown novel pathogens that may be designed or modified by AI systems in the future. The company, led by OpenAI, said it has raised $36 million so far. The company plans to begin human clinical trials of its avian influenza and other influenza virus family antibody drugs next year.